Quantification of clofarabine in urine and plasma by LC-MS/MS: suitable for PK study and TDM in pediatric patients with relapsed or refractory ALL

Clofarabine is approved for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years. Its pharmacokinetic (PK) exposure is strongly related to clinical outcomes and high risk of adverse reactions. PK-guided dosing of nucleoside analogs has t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xi, Jia, Xinbei, Tong, Weihang, Chen, Hui, Lei, Ning, Li, Guangrun, Tai, Jun, Li, Pengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2022
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672991/
https://www.ncbi.nlm.nih.gov/pubmed/36425201
http://dx.doi.org/10.1039/d2ra05843j

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672991/
https://www.ncbi.nlm.nih.gov/pubmed/36425201
http://dx.doi.org/10.1039/d2ra05843j

Ejemplares similares